If interested in this asset, please feel free to contact the BD team at DrugTimes immediately! Please send an email to BD@drugtimes.cn
The CNS track is heating up! Roche’s trontinemab data are positive! Interested in similar products? Please contact us quickly!
Recently, Roche announced the latest positive data of its investigational antibody trontinemab at the Alzheimer’s Association International Conference. In the Phase Ib/IIa Brainshuttle AD study, trontinemab demonstrated rapid and significant amyloid plaque clearance, with 91% of participants turning negative in amyloid PET assessments, and the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) remained below 5%.
Additionally, Roche plans to conduct the Phase III TRONTIER 1 and TRONTIER 2 clinical trials to evaluate the efficacy of trontinemab in early symptomatic Alzheimer’s disease, with the trials expected to be initiated later in 2025.
Moreover, Roche also plans to launch a new Phase III clinical trial to assess the therapeutic potential of trontinemab in patients with preclinical Alzheimer’s disease.
Trontinemab is a bispecific monoclonal antibody. It has a 2+1 structure, capable of bivalently binding to amyloid-beta (Aβ) plaques and monovalently binding to human transferrin receptor 1 (TfR1). Its targets are Aβ plaques and TfR1. The mechanism of action of Trontinemab involves binding to Aβ plaques to trigger Fc receptor-mediated phagocytosis by immune cells, thereby clearing Aβ plaques. Additionally, it binds to TfR1 and utilizes the transferrin receptor-mediated transport mechanism to enhance the drug’s ability to enter the brain, thus more effectively clearing Aβ plaques in the brain.
If you are interested in this type of product (ex-China rights), please contact us quickly!
Currently, DrugTimes BD Team is seeking potential partners for a new generation of Aβ/TfR1 bispecific antibodies with great potential.
Project Code：DT-20250718-082Project Name：New generation of β-amyloid antibodies with improved properties
Indication：Alzheimer’s Disease（AD）
Modality：Bispecific antibody
Target：AβxTfR1
Current stage：PCC
Highlight：
- Rapid accumulation into brain
- Superior anti-amyloid payload
- Mitigation of anemia risk with affinity refinement
Collaboration mode：license-out（ex-China right）
If interested in this asset, please feel free to contact the BD team at DrugTimes immediately! Please send an email to BD@drugtimes.cn
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 